Top

Published in:

01-05-2009 | Research Articles

Characteristics and outcome of prostate cancer with PSA <4 ng/ml at diagnosis: a population-based study

Authors: Marta Bonet, Arnaud Merglen, Gérald Fioretta, Elisabetta Rapiti, Isabelle Neyroud-Caspar, Roberto Zanetti, Raymond Miralbell, Christine Bouchardy

Published in: Clinical and Translational Oncology | Issue 5/2009

Title: Characteristics and outcome of prostate cancer with PSA <4 ng/ml at diagnosis: a population-based study
Authors: Marta Bonet
Arnaud Merglen
Gérald Fioretta
Elisabetta Rapiti
Isabelle Neyroud-Caspar
Roberto Zanetti
Raymond Miralbell
Christine Bouchardy
Publication date: 01-05-2009
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 5/2009
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-009-0359-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 5/2009

Introducing a new Educational Series: a step forward in Clinical and Translational Oncology dissemination

Lung cancer biology: a genetic and genomic perspective

Diagnosis of paediatric anaplastic large-cell lymphoma: a historical perspective from a single institution

Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer

Perpetuum mobile

Consensus on the treatment of pancreatic cancer in Spain

Keynote webinar | Spotlight on antibody–drug conjugates in cancer